NeuroThera Labs Hires RK Strategies To Lobby on Health Issues

Why It Matters

NeuroThera Labs Inc., a Canada-based clinical-stage pharmaceutical company, has retained RK Strategies Inc. to lobby on its behalf, according to a new client registration signed October 2. The filing marks NeuroThera's first appearance in federal lobbying records. The registration covers Health Issues as its sole issue area, with no specific legislation listed and the specific-issues section left blank. Around the time of the registration, the company was advancing Phase IIb clinical trials for a cannabinoid-based Tourette syndrome candidate and conducting a separate trial involving autism spectrum disorder symptoms, according to company announcements.

By the Numbers

The new client registration, with a registration date of August 25 and a signed date of October 2, lists a filing amount of $0. The sole lobbyist named is Ryan Kane, Senior Director of Government Affairs and Business Development at RK Strategies. Kane is a new lobbyist for this client; his recent RK Strategies filings include a second quarter 2026 termination for iPill Inc. and a second quarter 2026 report for Nexalin Technology Inc.

The Bottom Line

NeuroThera Labs Inc. filed a new client registration through RK Strategies Inc. that lists Health Issues (HCR). The dataset shows no earlier filings for the client, while the specific-issues section is blank.